Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 7;3(4):548-551.
doi: 10.1016/j.adro.2018.07.009. eCollection 2018 Oct-Dec.

Superficial radiation therapy in peyronie's disease: An effective and well-tolerated therapy

Affiliations

Superficial radiation therapy in peyronie's disease: An effective and well-tolerated therapy

Gunilla Pietsch et al. Adv Radiat Oncol. .

Abstract

Purpose: This study aimed to assess the safety, efficacy, and patient satisfaction of superficial radiation therapy in the treatment of Peyronie's disease (PD) in a retrospective analysis.

Methods and materials: We performed a retrospective analysis of 83 patients who underwent radiation therapy between 1999 and 2008 with 8 fractions of 4 Gy over a period of 6 months. With a mean follow-up time of 52 months, patients responded to a comprehensive questionnaire that covered patient characteristics, disease duration before radiation therapy, course of disease, treatment response, side effects, and patient satisfaction.

Results: After a mean follow-up time of 52 months, 78% of the treated patients reported that PD progression had stopped. Furthermore 47% of patients had a symptom regression. Only 7% of patients reported PD progression. The penile curvature was improved in 49% of patients, and plaque induration could be reduced in 42% of patients. Moreover, 71% of patients reported substantial pain relief, as measured by a visual analogue scale (1 = not satisfied; 10 = very satisfied). Treatment satisfaction was rated with a median of 8 in a visual analogue scale out of 10. Side effects included transient erythema in 38.6% of patients and 9.6% reported of transient or chronic dryness. No severe side effects were observed.

Conclusions: Radiation therapy for PD in the disease's early stages proved to be a safe and well-tolerated method with good results in pain relief, especially in patients aged <62 years. No serious adverse events or malign transformations are expected using doses up to 32 Gy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Campell J., Alzubaidi R. Understanding the cellular basis and pathophysiology of Peyronie's disease to optimize treatment for erectile dysfunction. Transl Androl Urol. 2017;6:46–59. - PMC - PubMed
    1. Schwarzer U., Sommer F., Klotz T., Braun M., Reifenrath B., Engelmann U. The prevalence of Peyronie's disease: Results of a large survey. BJU Int. 2001;88:727–730. - PubMed
    1. Stuntz M., Perlaky A., Des Vignes F., Kyriakides T., Glass D. The prevalence of Peyronie's disease in the United States: A population-based study. PLoS One. 2016;11:e0150157. - PMC - PubMed
    1. Ji J., Tian Y., Zhu Y.Q., Zhang L.Y., Ji S.J., Huan J. Ionizing irradiation inhibits keloid fibroblast cell proliferation and induces premature cellular senescence. J Dermatol. 2015;42:56–63. - PubMed
    1. Chong W., Tan R.B. Injectable therapy for Peyronie's disease. Transl Androl Urol. 2016;5:310–317. - PMC - PubMed

LinkOut - more resources